INNMF
Amplia Therapeutics Limited·Healthcare
0.09
0.000%(+0.00)
Close PriceLast Updated: — ET
52W L: $0.0352W H: $0.27
INNMF NEWS
proactiveinvestors.com
Mar 24
Altona Rare Earths shares jump 11% as gallium results exceed expectations at Mozambique project
Altona Rare Earths, the London-listed critical materials explorer, saw its shares rise 11% to 3.11 pence on Tuesday after reporting that gallium...
proactiveinvestors.com
Mar 23
Amplia flags key ACCENT milestone as 5 complete responses sharpen narmafotinib case in pancreatic cancer
Amplia Therapeutics Ltd (ASX:ATX, OTCQB:INNMF)'s ACCENT trial has reached an important milestone after an independent central review confirmed five complete...
proactiveinvestors.com
Mar 23
X‑Energy files to go public on the Nasdaq, eyes $300M raise
US nuclear technology developer X‑Energy has filed paperwork with the Securities and Exchange Commission to launch an initial public offering on Nasdaq,...
globenewswire.com
Mar 11
Amplia Therapeutics to Present at the Life Sciences Investor Forum on March 12th
The Company invites individual and institutional investors, as well as advisors and analysts with an interest in the life sciences sector, to attend live, interactive presentations at VirtualInvestorConferences.com The Company invites individual and institutional investors, as well as advisors and analysts with an interest in the life sciences sector, to attend live, interactive presentations at VirtualInvestorConferences.com
globenewswire.com
Mar 9
Poster Presentation Demonstrating Combination Benefit of Narmafotinib in Preclinical Kras-Mutated Cancer Models
HIGHLIGHTS Amplia's lead drug narmafotinib enhances the activity of kRAS inhibitors in multiple preclinical cancer models presented at US conference Data showing narmafotinib activity in preclinical models of pancreatic cancer, lung cancer and ovarian cancer are presented The development of kRAS inhibitors for different types of solid tumors is currently an area of intense global activity Melbourne, Australia, March 09, 2026 (GLOBE NEWSWIRE) -- Amplia Therapeutics Limited (ASX:ATX; OTCQB:INNMF), (“Amplia” or the “Company”), announces that compelling data describing new clinical opportunities for its lead drug narmafotinib was presented at the AACR Special Conference in Cancer Research: RAS Oncogenesis and Therapeutics in Los Angeles, California on Friday March 6. The poster presentation discloses preclinical data demonstrating that the Company's best-in-class FAK inhibitor narmafotinib enhances the activity of a new class of drugs called kRAS inhibitors in various models of cancer.
globenewswire.com
Feb 11
Amplia Therapeutics Announces Opening of US Sites for Amplicity Pancreatic Cancer Trial
Melbourne, Australia, Feb. 11, 2026 (GLOBE NEWSWIRE) -- HIGHLIGHTS Two US-based sites have completed trial initiation activities for the AMPLICITY trial in pancreatic cancer These sites join the two Australian sites already open and recruiting patients Three additional US sites are expected to be open in the coming weeks Amplia Therapeutics Limited (ASX:ATX; OTCQB:INNMF), (“Amplia” or the “Company”), announces that two (2) sites in the US have been initiated and will shortly be commencing recruitment activities for the AMPLICITY trial. The two sites – University of California, Irvine (Irvine, Calif.
